Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG

Sangeetha Iyer, Kausalya Murthy, Zachary Parton, Hillary Tsang, Feba S. Sam, Nina DiPrimio, Jessica Lao, View ORCID ProfileEthan O. Perlstein
doi: https://doi.org/10.1101/626697
Sangeetha Iyer
1Perlara PBC, 2625 Alcatraz Ave #435, Berkeley, California USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kausalya Murthy
1Perlara PBC, 2625 Alcatraz Ave #435, Berkeley, California USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zachary Parton
1Perlara PBC, 2625 Alcatraz Ave #435, Berkeley, California USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hillary Tsang
1Perlara PBC, 2625 Alcatraz Ave #435, Berkeley, California USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Feba S. Sam
1Perlara PBC, 2625 Alcatraz Ave #435, Berkeley, California USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nina DiPrimio
1Perlara PBC, 2625 Alcatraz Ave #435, Berkeley, California USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Lao
1Perlara PBC, 2625 Alcatraz Ave #435, Berkeley, California USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ethan O. Perlstein
1Perlara PBC, 2625 Alcatraz Ave #435, Berkeley, California USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ethan O. Perlstein
  • For correspondence: ethan@perlara.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Phosphomannomutase 2 deficiency, or PMM2-CDG, is the most common congenital disorder of glycosylation affecting over 1,000 patients globally. PMM2 encodes an ancient metabolic enzyme that forms an obligate dimer that catalyzes an initial step in the conserved pathway leading to N-linked glycosylation of proteins in every cell of every animal throughout its life. All PMM2-CDG patients have at least some residual PMM2 enzymatic activity because complete loss of function is incompatible with life in humans as well as in yeast, flies, fish and mice. Here we describe the first nematode model of PMM2-CDG genetically engineered with the common F119L dimerization-defective patient allele, which has reduced PMM2 enzymatic activity, a constitutively activated ER stress response and an increased sensitivity to proteasome inhibition by bortezomib. We describe an unbiased phenotypic screen to identify FDA approved drugs and generally recognized as safe natural products that suppress bortezomib toxicity in PMM2 F119L homozygote mutant worms. Nine worm repurposing hits from this study and three yeast repurposing hits from a previous study were tested for their effect on PMM2 enzymatic activity in F119/R141H patient fibroblasts in a 96-well-plate assay. The yeast hit alpha-cyano-hydroxycinnamic acid (CHCA) and the worm hit pyrogallin rescue PMM2 enzymatic activity by 65.5% and 23% in PMM2 fibroblasts, respectively. CHCA shares the carboxylic acid-containing pharmacophore of aldose reductase inhibitors. We tested commercially available ARIs in worms and fibroblasts and we found that only epalrestat reproducibly rescues PMM2 enzymatic activity in both species. Epalrestat elevated PMM2 enzymatic activity in patient fibroblasts by 30% over baseline. Epalrestat reduced ER stress marker expression and increased PMM2 mRNA levels in PMM2 F119L homozygote mutant worms by a mechanism that appears to involve the transcriptional regulator NRF2. Epalrestat is the only safe, orally bioavailable and brain penetrant aldose reductase inhibitor approved for use in humans, and the first small molecule potentiator of PMM2 enzymatic activity.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted May 03, 2019.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
Sangeetha Iyer, Kausalya Murthy, Zachary Parton, Hillary Tsang, Feba S. Sam, Nina DiPrimio, Jessica Lao, Ethan O. Perlstein
bioRxiv 626697; doi: https://doi.org/10.1101/626697
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
Sangeetha Iyer, Kausalya Murthy, Zachary Parton, Hillary Tsang, Feba S. Sam, Nina DiPrimio, Jessica Lao, Ethan O. Perlstein
bioRxiv 626697; doi: https://doi.org/10.1101/626697

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Toxicology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4838)
  • Biochemistry (10729)
  • Bioengineering (8005)
  • Bioinformatics (27166)
  • Biophysics (13930)
  • Cancer Biology (11079)
  • Cell Biology (15977)
  • Clinical Trials (138)
  • Developmental Biology (8757)
  • Ecology (13228)
  • Epidemiology (2067)
  • Evolutionary Biology (17306)
  • Genetics (11663)
  • Genomics (15877)
  • Immunology (10986)
  • Microbiology (25979)
  • Molecular Biology (10600)
  • Neuroscience (56311)
  • Paleontology (416)
  • Pathology (1727)
  • Pharmacology and Toxicology (2998)
  • Physiology (4528)
  • Plant Biology (9583)
  • Scientific Communication and Education (1610)
  • Synthetic Biology (2668)
  • Systems Biology (6954)
  • Zoology (1507)